-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Intravenous immune globulin (of IVIG) is a new treatment of systemic sclerosis SSc
.
It is speculated that IVIG has immunomodulatory and antifibrotic activities
immunity
We evaluated data from 24 patients (21 women, 3 men) with refractory diffuse SSc skin involvement (mean age, 52.
13 years)
.
IVIG infusion was started between 2002 and 2019 at a dose of 2 g/Kg body weight for 4 consecutive days/month
As a result, the study ultimately identified 17 papers (183 total patients treated)
.
The studies were classified according to the organ involvement considered in each study, as well as the prescribed dose (high or low dose) and treatment regimen
Blood vessel
Taken together, data from this SLR and retrospective study suggest that IVIG can improve skin involvement and reduce mRSS, especially in those patients who are refractory to other standard-of-care therapies, or in patients with concomitant myositis.
Original source:
Elana Agostini, et al.
Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experienceleave a message here